Study on the Role of Short Peptide LCKLSL Targeting ANXA2 in Retinal Neovascularization

作者：Jiale Bai, Yini Wang, Shihong Zhao · 发表于：In Vivo · 年份：2026 · DOI：10.21873/invivo.14291 · 研究领域：S100 Proteins and Annexins、Retinopathy of Prematurity Studies、Blood Coagulation and Thrombosis Mechanisms

BACKGROUND/AIM: Annexin A2 (ANXA2), functioning as a co-receptor for tissue plasminogen activator (tPA) and plasminogen, plays a critical role in retinal neovascularization (RNV). The hexapeptide LCKLSL competitively inhibits ANXA2 activity, offering a potential therapeutic strategy for RNV in retinopathy of prematurity (ROP). This study investigated the efficacy and biosafety of LCKLSL in suppressing RNV using an oxygen-induced retinopathy (OIR) model in C57BL/6J mice. MATERIALS AND METHODS: experiments using hypoxia-induced human umbilical vein endothelial cells (HUVECs) assessed cellular safety (CCK-8 and TUNEL assays) and therapeutic effects on migration (Wound healing assay), angiogenesis (Matrigel tube formation), and invasion (Transwell assay). RESULTS: , LCKLSL inhibited HUVEC migration, tube formation, and invasion under hypoxia. CONCLUSION: LCKLSL acts as a potent ANXA2-targeted inhibitor of pathological angiogenesis and demonstrates a favorable biosafety profile, highlighting its promising therapeutic potential for the treatment of RNV-related disorder.